Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer

Clinical effects of doxifluridine (group A, 600 mg/ body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 8 4.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, resp ectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse react ion were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions we re fully controlled and TTP was prolonged.